British Medical Bulletin 52:556-574 (1996)
© 1996 The British Council
research-article |
Advances in psychopharmacology schizophrenia
Department of Psychiatry, University of Edinburgh Edinburgh, UK
Abstract
Every so often in the history of medicine, events occur which in retrospect seem to mark a defining moment. For psychiatry, the decade of the 1950s uses one such moment. On 28 December 1951, J. Sigwald started sols chlorpromazine treatment of a 57-year-old psychotic lady and, thereby, it might be argued, began the modern era of psychopharmacology.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
R. A. Bantick, J. F. W. Deakin, and P. M. Grasby The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol, January 1, 2001; 15(1): 37 - 46. [Abstract] [PDF] |
||||
![]() |
M. E Downing, J. G Phillips, J. L Bradshaw, K. S Vaddadi, and C. Pantelis Cue dependent right hemineglect in schizophrenia: a kinematic analysis J. Neurol. Neurosurg. Psychiatry, October 1, 1998; 65(4): 454 - 459. [Abstract] [Full Text] |
||||

